For antibody drug conjugates to reach their full potential, developers should focus on addressing current challenges such as safety and efficacy.
Andreas Dreps
Advertisement
Senior VP and Global Head Drug Development Unit, ICON plc
Articles by Andreas Dreps
Advertisement
Latest Updated Articles
Overcoming Challenges in the Development of Antibody Drug ConjugatesPublished: May 7th 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AI in Action: Breaking Down Clinical Trial Bottlenecks
2
Unlocking the Potential of Agentic AI to Reduce Trial Delays
3
Balancing Human Oversight and Automation in AI-Driven Trials
4
2025 SCRS Global Site Solutions Summit: How Standardized CDAs Can Accelerate Site Activation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
